Specific hormonal contraceptives for the treatment of HMB
| . | Estrogen: EE . | Progestin . | Comments . |
|---|---|---|---|
| Combined hormonal contraceptives | |||
| Combined oral contraceptive pills | Packaged as 21 d of active pills or 21 d of active pills + 7 d of placebo pills | ||
| 20 μg EE | 1 mg norethindrone | Available in an extended cycle regimen with 24 d of active pills + 4 d of placebo | |
| 30 μg EE | 1.5 mg norethindrone | — | |
| 35 μg EE | 1 mg norethindrone | — | |
| 20 μg EE | 0.1 mg levonorgestrel | — | |
| 20 μg EE | 90 μg levonorgestrel | Marketed as a continuous regimen | |
| 30 μg EE | 1.5 mg levonorgestrel | Available in an extended cycle regimen with 84 d of active pills + 7 d of placebo or 10 μg of EE | |
| Patch | 20 μg EE daily | 150 μg of norelgestromin daily | Applied weekly for 3 wk out of 4 |
| Ring | 15 μg EE daily | 120 mcg of etonogestrel daily | Worn 3 wk out of 4 |
| Progestin-only contraceptives | |||
| Pills | — | 0.35 mg norethindrone | Daily |
| Intramuscular injection | — | 150 mg DMPA | Every 3 mo |
| Subcutaneous injection | — | 104 mg DMPA | Every 3 mo |
| Subcutaneous implant | — | 68 mg etonogestrel | Slowly released over ≥3 y; ∼60 μg daily after 3 mo, which slowly decreases to 30 μg daily at the end of 2 y |
| Intrauterine device | — | 52 mg levonorgestrel | Release rate of 20 μg daily, FDA-approved for 5 y of use |
| — | 13.5 mg levonorgestrel | Release rate of 14 μg daily, FDA approved for 3 y of use | |
| . | Estrogen: EE . | Progestin . | Comments . |
|---|---|---|---|
| Combined hormonal contraceptives | |||
| Combined oral contraceptive pills | Packaged as 21 d of active pills or 21 d of active pills + 7 d of placebo pills | ||
| 20 μg EE | 1 mg norethindrone | Available in an extended cycle regimen with 24 d of active pills + 4 d of placebo | |
| 30 μg EE | 1.5 mg norethindrone | — | |
| 35 μg EE | 1 mg norethindrone | — | |
| 20 μg EE | 0.1 mg levonorgestrel | — | |
| 20 μg EE | 90 μg levonorgestrel | Marketed as a continuous regimen | |
| 30 μg EE | 1.5 mg levonorgestrel | Available in an extended cycle regimen with 84 d of active pills + 7 d of placebo or 10 μg of EE | |
| Patch | 20 μg EE daily | 150 μg of norelgestromin daily | Applied weekly for 3 wk out of 4 |
| Ring | 15 μg EE daily | 120 mcg of etonogestrel daily | Worn 3 wk out of 4 |
| Progestin-only contraceptives | |||
| Pills | — | 0.35 mg norethindrone | Daily |
| Intramuscular injection | — | 150 mg DMPA | Every 3 mo |
| Subcutaneous injection | — | 104 mg DMPA | Every 3 mo |
| Subcutaneous implant | — | 68 mg etonogestrel | Slowly released over ≥3 y; ∼60 μg daily after 3 mo, which slowly decreases to 30 μg daily at the end of 2 y |
| Intrauterine device | — | 52 mg levonorgestrel | Release rate of 20 μg daily, FDA-approved for 5 y of use |
| — | 13.5 mg levonorgestrel | Release rate of 14 μg daily, FDA approved for 3 y of use | |
DMPA, depot medroxyprogesterone acetate; EE, ethinyl estradiol; FDA, Food and Drug Administration.